Table 4 Clinical trials of PDT for urological cancers
From: Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges
Photosensitizers | Conditions | Locations | Status | NCT number |
|---|---|---|---|---|
TLD1433 | NMIBC refractory to BCG | Canada | Phase 1 (C) | NCT03053635 |
NMIBC refractory to BCG | United States; Canada | Phase 2 (R) | NCT03945162 | |
Photofrin® | Superficial BC | United States | Phase 1/2 (C) | NCT00322699 |
Hexvix® | Intermediate or high-risk BC | NA | Phase 1 (C) | NCT01303991 |
Motexafin Lutetium | Adenocarcinoma of the prostate; recurrent PCa; stage I PCa; stage IIA PCa; stage IIB PCa | United States | Phase 1 (T) | NCT00005067 |
WST09 | PCa | Canada | Phase 2 (C) | NCT00305929 |
Recurrent or persistent localized carcinoma of the prostate following radiation therapy failure | Canada | Phase 2 (C) | NCT00308919 | |
PCa | Canada | Phase 2/3 (T) | NCT00312442 | |
WST11 | PCa | Canada; France; United Kingdom | Phase 2 (C) | NCT00707356 |
PCa | United States | Phase 1/2 (C) | NCT00946881 | |
PCa | France; Netherlands; United Kingdom | Phase 2 (C) | NCT00975429 | |
PCa | Belgium; Finland; France; Germany; Italy; Netherlands; Spain; Sweden; Switzerland; United Kingdom | Phase 3 (C) | NCT01310894 | |
PCa | Mexico; Panama; Peru | Phase 3 (C) | NCT01875393 | |
Localized PCa | United States | Phase 2 (ANR) | NCT03315754 | |
Low Risk PCa | France | Phase 4 (T) | NCT03849365 | |
Localized PCa | United States | Phase 3 (W) | NCT04225299 | |
Upper tract urothelial carcinoma | United States | Phase 1 (ANR) | NCT03617003 | |
Renal cancer | United Kingdom | Phase 1/2 (T) | NCT01573156 | |
Transitional cell cancer of renal pelvis and ureter | United States; France | Phase 3 (R) | NCT04620239 | |
Verteporfin | Recurrent PCa | United States; Canada; United Kingdom | Phase 1 (U) | NCT03067051 |